Polyrizon Ltd. Ordinary Shares (PLRZ)

Polyrizon Ltd. (PLRZ) has finalized contracting with all five U.S. clinical sites for its 120-patient "first-in-human" study of NASARIX™ Allergy Blocker (PL-14), marking a significant operational milestone. The prospective, multicenter, randomized trial will evaluate NASARIX™ against isotonic saline nasal spray in patients with seasonal allergic rhinitis, focusing on efficacy, safety, and tolerability. The company is now moving into patient pre-screening and enrollment, timed to align with relevant allergy seasons.

Polyrizon has finalized agreements with all five clinical sites for its NASARIX Allergy Blocker study, marking a significant step toward patient enrollment. The study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to assess the efficacy, safety, and tolerability of NASARIX in up to 120 patients with seasonal allergic rhinitis. Patient enrollment will be timed to coincide with relevant allergy seasons to evaluate the product under real-world conditions.

Polyrizon Ltd. (NASDAQ:PLRZ) has finalized contracting with all five clinical sites for its NASARIX Allergy Blocker study. The first-in-human trial will evaluate the efficacy, safety, and tolerability of NASARIX in up to 120 patients with seasonal allergic rhinitis. The study will monitor total nasal symptom scores, quality of life, and adverse events, with patient enrollment timed to coincide with allergy seasons.

Polyrizon (Nasdaq: PLRZ) announced the completion of contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker (PL-14) study, an intranasal hydrogel-based product for seasonal allergic rhinitis. This operational milestone allows the company to progress towards patient enrollment for the first-in-human trial, which will involve up to 120 patients randomized to receive either NASARIX or isotonic saline nasal spray. The primary endpoint will measure the mean daily reflective Total Nasal Symptom Score over 14 treatment days, with enrollment timed to coincide with relevant allergy seasons.

MMCAP International Inc. SPC and MM Asset Management Inc. have disclosed a 9.6% beneficial stake in Polyrizon Ltd. (PLRZ), owning 199,470 ordinary shares. This information was reported in an amended Schedule 13G filing, indicating shared voting and dispositive power over these shares. The filing notes that the ownership is passive and not intended to influence control of the issuer.